Practical support for antibody programs.
An independent consultancy for biotech startups, from antibody discovery to early development.
Request an intro callQuestions clients bring
Each one gets a clear recommendation with the reasoning behind it, not a list of options.
- Which modality and antibody format fit this target?
- Is our assay strategy strong enough to pick a lead on?
- Which lead candidate do we advance, and which do we drop?
- What does a realistic plan to the clinic look like, with clear Go/No-Go gates?
- What does this dataset really tell us, and what do we tell investors?
Where we step in
One advisor from target biology to a milestone-driven development plan, so early decisions still hold up later.
-
Target and modality
Target biology, modality selection and antibody format choice.
-
Discovery
Discovery strategy, assay strategy and oversight of the work at CROs.
-
Lead triage
Data review, lead triage and the call on which molecules to advance.
-
Preclinical planning
Development plan with timelines, risk areas and milestones.
-
Go/No-Go decisions
Decision gates and clear recommendations for founders, investors and R&D teams.
I was in part responsible for the antibody programs that became VectorY’s lead candidates in ALS and Huntington’s disease, contributing to a €129 million Series A. The lead program is in a Phase 1/2 trial with FDA Fast Track designation.
Recent work
Client names and targets stay confidential. The kind of work does not have to.
-
Format
Triaged trispecific antibody formats and delivered one recommended design with its rationale.
-
CRO selection
Compared two competing CRO proposals for an IgG reformatting and screening campaign, scope against budget.
-
Optimization
Steered an affinity maturation campaign at a CRO and advised which clones to advance.
-
Manufacturing
Mapped and approached CDMOs for multiple antibody modalities.
-
Intelligence
Competitive and patent read on a clinical-stage antibody, down to how it is manufactured.
Recent development and clinical antibody papers
A short selection from development and the clinic. The summaries are in our own words. Follow the link for the paper itself.
mAbs · 13 Nov 2026
Developability of 181 single-domain antibodies, measured
A Merck team characterised 181 untagged VH domains for titer, purity, aggregation, thermal stability and hydrophobicity, and compared them with mAb acceptance criteria and approved VH drugs.
Read the paperNature Medicine · 23 Oct 2026
Invikafusp alfa: a dual T cell agonist in solid tumors
Phase 1/2 START-001 trial in mostly checkpoint-resistant tumors. No maximum tolerated dose was reached in 34 patients, and 4 of 27 responded at the two optimal doses.
Read the paperBlood · 16 Nov 2026
Etentamig: a monthly BCMA bispecific in myeloma
Pooled phase 1 data from 146 heavily pretreated patients, of whom 66% responded. The low-affinity CD3 arm is meant to limit cytokine release.
Read the paperCPT: Pharmacometrics & Systems Pharmacology · Nov 2026
A first human dose without a cross-reactive species
AZD2796 binds neither monkey nor rodent LILRB2. A surrogate antibody and receptor occupancy modelling supported a 30 mg starting dose.
Read the paperJournal of Hematology & Oncology · 31 Oct 2026
PD-(L)1×VEGF bispecifics: the 2026 trial readouts
An overview of this year’s results for the class, led by the phase 3 HARMONi-6 survival benefit for ivonescimab plus chemotherapy in squamous lung cancer.
Read the paperNature Communications · 30 Sep 2026
AER002 in Long COVID: a clear negative result
Placebo-controlled phase 2a trial in 36 participants. The antibody was safe and well tolerated, with no difference from placebo on the primary endpoint.
Read the paperThree ways to engage
Program and project lead
Set days per month inside your team, aligning scientific priorities, team execution and investor needs.
For startups before their first senior biologics hire.
Scoped project
One question, one deliverable: a modality recommendation, a lead triage, a development plan.
For teams with a decision due this quarter.
Independent data review
A critical read of a dataset or program to strengthen decisions and identify risks early.
For founders, investors and R&D teams.
“Let’s make things that work.”
Wouter Pos, PhD
Founder and independent biotech consultant, Concido Therapeutics, since 2024. Through Concido I have contributed to antibody programs at three early-stage biotech companies.
- 20+
- years in antibody and VHH discovery and engineering
- 7+
- patents as co-inventor
- 4
- disease areas: oncology, autoimmunity, obesity and cardiovascular disease
AIMM Therapeutics
Co-inventor on the AML antigen patent family and on patents for AAV-delivered antibody therapeutics; co-author on the AT1412 (CD9) work.
BioSemia
Scientific Director: I lead the science behind AI tools for preclinical imaging and help biotech teams put AI to practical use in their own data and workflows.
Thirty minutes, no obligation.
Tell us where your program stands. You will hear plainly whether Concido can help, under a CDA if needed.
You work with me directly. No junior team, no handover.